Exagen Diagnostics has entered into an agreement with non-profit health services company CareFirst BlueCross BlueShield to clinically study its AVISE Lupus test.

Under the terms of the agreement, certain CareFirst members will gain access to the test that is designed to assist in the differential diagnosis of systemic lupus erythematosus (SLE).

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

SLE is known to be the most common form of lupus, which is an incurable autoimmune rheumatic disease. SLE is considered difficult to detect and currently lacks diagnostic tests.

“The test and algorithm have been prospectively validated in clinical trials conducted in a total of over 1,200 patients. AVISE Lupus is said to have demonstrated better diagnostic accuracy compared to standard biomarkers.”

AVISE Lupus test is a ten-marker diagnostic that comprises cell-bound complement activation products (CB-CAPs) and SLE related markers. It is designed to maximise accuracy and minimise time to diagnosis.

The test and its algorithm have been prospectively validated in clinical trials conducted in a total of more than 1,200 patients. AVISE Lupus is said to have demonstrated better diagnostic accuracy compared to standard biomarkers alone.

The primary objective of the latest study is to evaluate the efficacy and cost-effectiveness of the test in primary care as well as rheumatology settings.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

CareFirst plans to use the study findings to ensure maximum benefit to patients while making coverage decisions for AVISE Lupus in the future.

Exagen Diagnostics chief medical officer Arthur Weinstein said: “This is a unique collaboration which has the potential of ultimately benefitting patients with SLE by enabling earlier diagnosis and consequently earlier and more appropriate treatment.”

As part of the agreement, Exagen and CareFirst will also conduct an exploratory study to investigate the impact of AVISE Lupus test results on primary care physician practice referral patterns.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact